Sarcoma treatment in the era of molecular medicine

TGP Grünewald, M Alonso, S Avnet… - EMBO molecular …, 2020 - embopress.org
Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers.
Although constituting only 1% of all human malignancies, sarcomas represent the second …

[HTML][HTML] The role of photoactivated and non-photoactivated verteporfin on tumor

C Wei, X Li - Frontiers in pharmacology, 2020 - frontiersin.org
Verteporfin (VP) has long been clinically used to treat age-related macular degeneration
(AMD) through photodynamic therapy (PDT). Recent studies have reported a significant anti …

[HTML][HTML] Fusion protein-driven IGF-IR/PI3K/AKT signals deregulate Hippo pathway promoting oncogenic cooperation of YAP1 and FUS-DDIT3 in myxoid liposarcoma

R Berthold, I Isfort, C Erkut, L Heinst, I Grünewald… - Oncogenesis, 2022 - nature.com
Myxoid liposarcoma (MLS) represents a common subtype of liposarcoma molecularly
characterized by a recurrent chromosomal translocation that generates a chimeric FUS …

[HTML][HTML] AMOTL1 enhances YAP1 stability and promotes YAP1-driven gastric oncogenesis

Y Zhou, J Zhang, H Li, T Huang, CC Wong, F Wu, M Wu… - Oncogene, 2020 - nature.com
Hippo signaling functions to limit cellular growth, but the aberrant nuclear accumulation of its
downstream YAP1 leads to carcinogenesis. YAP1/TEAD complex activates the oncogenic …

[HTML][HTML] Metabolic landscapes in sarcomas

R Miallot, F Galland, V Millet, JY Blay… - Journal of hematology & …, 2021 - Springer
Metabolic rewiring offers novel therapeutic opportunities in cancer. Until recently, there was
scant information regarding soft tissue sarcomas, due to their heterogeneous tissue origin …

[HTML][HTML] YAP, TAZ, and Hippo-Dysregulating Fusion Proteins in Cancer

JH Driskill, JK Dermawan… - Annual Review of …, 2024 - annualreviews.org
Gene fusions are well-known drivers of cancer and are potent targets for molecular therapy.
An emerging spectrum of human tumors harbors recurrent and pathognomonic gene fusions …

Prognostic value of nuclear morphometry in myxoid liposarcoma

K Kawaguchi, K Kohashi, T Iwasaki… - Cancer …, 2023 - Wiley Online Library
Myxoid liposarcoma (MLS) accounts for 20%‐30% of liposarcoma and the round cell
component (RCC) is believed to be a specific poor prognostic factor. However, the RCC …

[HTML][HTML] FUS-DDIT3 fusion oncoprotein expression affects JAK-STAT signaling in myxoid liposarcoma

S Dolatabadi, E Jonasson, L Andersson… - Frontiers in …, 2022 - frontiersin.org
Myxoid liposarcoma is one of the most common sarcoma entities characterized by FET
fusion oncogenes. Despite a generally favorable prognosis of myxoid liposarcoma …

[HTML][HTML] A review of retroperitoneal liposarcoma genomics

R Tyler, K Wanigasooriya, P Taniere, M Almond… - Cancer treatment …, 2020 - Elsevier
Retroperitoneal liposarcomas are rare tumours that carry a poorer prognosis than their
extremity counterparts. Within their subtypes–well differentiated (WDL), dedifferentiated …

[HTML][HTML] Genetic, epigenetic and transcriptome alterations in liposarcoma for target therapy selection

EA Lesovaya, TI Fetisov, BY Bokhyan, VP Maksimova… - Cancers, 2024 - mdpi.com
Simple Summary Liposarcoma is the most widespread soft-tissue sarcoma in adults. This
review summarizes the molecular genetics and epigenetics of the main liposarcoma …